Biomarkers in pulmonary infections: a clinical approach
Ready to transform your patient retention strategy
Disclosures: Arunkumar Krishnan: Nothing to Disclose, Diptasree Mukherjee: Nothing to Disclose, Carolin Schneider: Nothing to Disclose, Tinsay Woreta: Nothing to Disclose, Saleh Alqahtani: Nothing to Disclose 1624 SAROGLITAZAR IS MORE EFFECTIVE THAN SIMVASTATIN IN REDUCING STEATOSIS IN PATIENTS WITH MET-ALD Anand Kulkarni 1 Ramyasri Ramagundam 2 Zaid Mohammed Gangdany 2 Mithun Sharma 3 Manasa Alla 2 Shantan Venishetty 2 Sowmya T R 2 Padaki Nagaraja Rao 2 Nageshwar Reddy 2 , 1 Asian Institute of Gastroenterology, 2 AIG Hospitals, 3 ASIAN INSTITUTE OF GASTROENTROLOGY PVT LTD Background: MetALD is the new term proposed to identify patients with steatotic liver disease, who concomitantly consume alcohol (210-420 g/week)
Obesity Pillars , 15 , 100181
The court previously denied an initial request to halt the law before it took effect in May 2026
For more information, contact us today or book an appointment online now